SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jonathon B. Cohen, Jeffrey M. Switchenko, Jean L. Koff, Rajni Sinha, Jonathan L. Kaufman, H. Jean Khoury, Nassoma Bumpers, Amanda Colbert, Amanda Hutchison-Rzepka, Loretta J. Nastoupil, Leonard T. Heffner, Amelia A. Langston, Mary Jo Lechowicz, Sagar Lonial, Christopher R. Flowers, A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma, British Journal of Haematology, 2015, 171, 4
  2. 2
    Tomoyuki Sakai, Yasufumi Masaki, Nozomi Otsuki, Ippei Sakamaki, Shinji Kishi, Takayoshi Miyazono, Yoshimasa Urasaki, Jun Murakami, Tomomi Satoh, Takuji Nakamura, Haruka Iwao, Akio Nakajima, Takafumi Kawanami, Miyuki Miki, Yoshimasa Fujita, Masao Tanaka, Toshihiro Fukushima, Toshiro Okazaki, Takanori Ueda, Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group, Medical Oncology, 2015, 32, 9

    CrossRef

  3. 3
    Zhengjia Chen, Ye Cui, Taofeek K. Owonikoko, Zhibo Wang, Zheng Li, Ruiyan Luo, Michael Kutner, Fadlo R. Khuri, Jeanne Kowalski, Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials, Contemporary Clinical Trials, 2014, 37, 2, 322

    CrossRef

  4. 4
    Michael Craig, Wahid T. Hanna, Fernando Cabanillas, Chien-Shing Chen, Dixie-Lee Esseltine, Rachel Neuwirth, Owen A. O'Connor, Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma, British Journal of Haematology, 2014, 166, 6
  5. 5
    Zhengjia Chen, Mourad Tighiouart, Jeanne Kowalski, Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials, Contemporary Clinical Trials, 2012, 33, 5, 949

    CrossRef

  6. 6
    Mourad Tighiouart, Galen Cook-Wiens, André Rogatko, Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials, Journal of Probability and Statistics, 2012, 2012, 1

    CrossRef

  7. 7
    Mourad Tighiouart, André Rogatko, Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control, Journal of Probability and Statistics, 2012, 2012, 1

    CrossRef

  8. 8
    Flint Russett, Recent Publications on Medications and Pharmacy, Hospital Pharmacy, 2012, 47, 9, 741

    CrossRef